For a variety of advanced solid tumors, the incidence of fatal adverse effects is significantly higher when bevacizumab is added to chemotherapy than when chemotherapy is used alone, the results of a meta-analysis have shown. The most common fatal adverse effects associated with the bevacizumab (Avastin), a monoclonal antibody targeting the vascular endothelial growth factor (VEGF), were hemorrhage, neutropenia, and gastrointestinal tract perforation, said Dr. Vishal Ranpura and associates at Stony...